## **DEFINITION TOOL FOR AIDS GRANTS**

AIDS GRANTS MUST EITHER HAVE AT LEAST ONE ITEM FROM SECTION A CHECKED (OTHER THAN NOT APPLICABLE) OR HAVE AN ITEM FROM SECTION B CHECKED AS WELL AS AN ITEM FROM SECTION C.

	Section A	Section B
	A1. Target population is HIV infected or tissues samples are from HIV infected individuals	□ B1. Target population is designated as "at risk" or "vulnerable" for HIV infection
	A2. Simian Immunodeficiency Virus (SIV) animal models or in vitro models using HIV or SIV	<ul> <li>B2. Target population has significant incidence and/oprevalence of HIV infection (e.g., minorities, women, IDUs, MSM, criminal justice)</li> </ul>
	A3. Study examines biological systems that influence HIV transmission/acquisition and/or progression (immune, neurological) and has HIV/AIDS as an independent or dependent variable	□ B3. Animal models (other than SIV) or in vitro systems that have potential to address HIV/AIDS
	A4. Research goals include a focus on training future HIV/AIDS researchers and investigators	□ B4. Not Applicable
HI ful an	A5. Project focuses on HIV/AIDS information dissemination V/AIDS is the focus of a research aim & HIV/AIDS is ly integrated throughout the application including alyses. Research addresses one or more of the lowing HIV/AIDS topics:	SECTION C
	□ A6. Prevention of acquisition and/or transmission of HIV	<ul> <li>C1. HIV/AIDS is incorporated in at least one research aim and appropriate methods and analyse are proposed</li> </ul>
	<ul> <li>A7. HIV virology, immunology, pathogenesis, and/or disease progression</li> <li>A8. HIV pharmacotherapy, including drug</li> </ul>	C2. Study examines specific HIV transmission routes and/or associated risk behaviors
	<ul> <li>interactions</li> <li>A9. HIV Vaccine related studies</li> <li>A10. Epidemiology of HIV/AIDS</li> <li>A11. Consequences of HIV (e.g., neurological, cardiovascular)</li> <li>A12. HIV/HCV comorbidity and/or opportunistic infections (OIs)</li> <li>A.13. Access, utilization, &amp; adherence to HIV medications</li> <li>A14. Drug abuse treatment as HIV prevention with specific HIV-related outcome measures and analyses</li> <li>A15. Controlled human laboratory studies that address specific HIV risk behaviors</li> <li>A16. HIV/AIDS treatment as HIV prevention with specific HIV-related outcome measures and analyses.</li> <li>A17. HIV/AIDS implementation science research</li> </ul>	<ul> <li>and/or associated risk benaviors</li> <li>C3. Research study has HIV/AIDS viral or host immunological response component(s) as independent or dependent variable</li> <li>C4. Psychosocial or sociological research on individuals and communities affected by HIV/AIDS with a specific AIM focused on reducing HIV/AIDS adverse consequences</li> <li>C5. Research study focuses on STIs or OIs in the context of HIV infection</li> <li>C6. Not Applicable</li> </ul>
	A18. Not Applicable	